{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:27:15Z","timestamp":1793212035354,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jaad.2023.10.072","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T16:29:52Z","timestamp":1706286592000},"page":"619-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Safety of dermatologic medications in pregnancy and lactation: An update - Part I: Pregnancy"],"prefix":"10.1016","volume":"91","author":[{"given":"Patrick","family":"McMullan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Yaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu M.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marti","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Murase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib1","doi-asserted-by":"crossref","first-page":"401.e1","DOI":"10.1016\/j.jaad.2013.09.010","article-title":"Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy","volume":"70","author":"Murase","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib2","doi-asserted-by":"crossref","first-page":"417.e1","DOI":"10.1016\/j.jaad.2013.09.009","article-title":"Safety of dermatologic medications in pregnancy and lactation part II. Lactation","volume":"70","author":"Butler","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/(SICI)1096-8628(19990917)86:3<242::AID-AJMG9>3.0.CO;2-U","article-title":"Maternal corticosteroid use and risk of selected congenital anomalies","volume":"86","author":"Carmichael","year":"1999","journal-title":"Am J Med Genet"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.072_bib4","doi-asserted-by":"crossref","first-page":"585.e1","DOI":"10.1016\/j.ajog.2007.05.046","article-title":"Maternal corticosteroid use and orofacial clefts","volume":"197","author":"Carmichael","year":"2007","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/jid.2010.392","article-title":"Safety of topical corticosteroids in pregnancy: a population-based cohort study","volume":"131","author":"Chi","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2023.10.072_bib6","article-title":"Safety of topical corticosteroids in pregnancy","volume":"2015","author":"Chi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2023.10.072_bib7","series-title":"Drugs during Pregnancy and Lactation: Treatment Options and Risk Assessment","author":"Schaefer","year":"2015"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.072_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z","article-title":"Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies","volume":"62","author":"Park-Wyllie","year":"2000","journal-title":"Teratology"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2020.03.075","article-title":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","article-title":"Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis","volume":"7","author":"Devasenapathy","year":"2023","journal-title":"Lancet Child Adolesc Heal"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2352-4642(22)00311-X","article-title":"Unboxing the black box on topical calcineurin inhibitors and cancer risk","volume":"7","author":"Tham","year":"2023","journal-title":"Lancet Child Adolesc Heal"},{"issue":"10","key":"10.1016\/j.jaad.2023.10.072_bib12","first-page":"905","article-title":"Safety of tacrolimus in pregnancy","volume":"60","author":"Nevers","year":"2014","journal-title":"Can Fam Physician"},{"issue":"7","key":"10.1016\/j.jaad.2023.10.072_bib13","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/TP.0b013e318278d367","article-title":"Interpreting tacrolimus concentrations during pregnancy and postpartum","volume":"95","author":"Hebert","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2023.10.072_bib14","series-title":"Dovonex(Calcipotriene) 0.005% [Package Insert]","year":"2015"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/ajd.12641","article-title":"Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration","volume":"59","author":"Rademaker","year":"2018","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2023.10.072_bib16","series-title":"Soriatane (Acitretin) Capsules [Package Insert]","year":"2017"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.072_bib17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0002-9343(90)90522-F","article-title":"Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease","volume":"88","author":"Kozlowski","year":"1990","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib18","first-page":"599","article-title":"Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester","volume":"99","author":"Nguyen","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/jcph.616","article-title":"Folic acid supplementation for pregnant women and those planning pregnancy: 2015 update","volume":"56","author":"Chitayat","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib20","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.072_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40264-013-0034-x","article-title":"Ciclosporin use during pregnancy","volume":"36","author":"Paziana","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2023.10.072_bib22","first-page":"57","article-title":"Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation","volume":"4","author":"Armenti","year":"2006","journal-title":"Clin Transpl"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/pde.12780","article-title":"Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study","volume":"33","author":"Tom","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/pde.12872","article-title":"Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure study","volume":"33","author":"Zane","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40257-022-00741-9","article-title":"Pharmacokinetics of roflumilast cream in chronic plaque psoriasis: data from phase I to phase III studies","volume":"24","author":"Thurston","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.10.072_bib27","series-title":"Zoryve (Roflumilast) [Package Insert]","year":"2022"},{"key":"10.1016\/j.jaad.2023.10.072_bib28","series-title":"Eucrisa (Crisabarole) Ointment [Package Insert]","year":"2016"},{"key":"10.1016\/j.jaad.2023.10.072_bib29","series-title":"Otezla (Apremilast) [Package Insert]","year":"2017"},{"key":"10.1016\/j.jaad.2023.10.072_bib30","series-title":"VTAMA (Tapinarof) [Package Insert]","year":"2022"},{"issue":"1-2","key":"10.1016\/j.jaad.2023.10.072_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00508-019-1448-y","article-title":"Immunosuppressives and biologics during pregnancy and lactation: a consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation","volume":"131","author":"Puchner","year":"2019","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jaad.2023.10.072_bib32","series-title":"Xeljanz (Tofacitinib) [Package Insert]","year":"2018"},{"key":"10.1016\/j.jaad.2023.10.072_bib33","series-title":"Rinvoq (Upadacitinib) Extended-Release Tablet [Package Insert]","year":"2019"},{"key":"10.1016\/j.jaad.2023.10.072_bib34","series-title":"Jakafi (Ruxolitinib) Tablets [Package Insert]","year":"2011"},{"issue":"8","key":"10.1016\/j.jaad.2023.10.072_bib35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"issue":"12","key":"10.1016\/j.jaad.2023.10.072_bib36","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2023.10.072_bib37","series-title":"Sotyktu (Deucravacitinib) [Package Insert]","year":"2022"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.072_bib38","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ecco-jcc\/jjad005","article-title":"Vaccines in children exposed to biological agents in utero and\/or during breastfeeding: are they effective and safe?","volume":"17","author":"Gisbert","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"10","key":"10.1016\/j.jaad.2023.10.072_bib39","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1093\/rheumatology\/keac141","article-title":"A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero","volume":"61","author":"Goulden","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.072_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.jaad.2023.10.072_bib41","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/00365521.2013.812141","article-title":"Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-\u03b1 therapy during pregnancy: three-center study","volume":"48","author":"Bortlik","year":"2013","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.072_bib42","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2010.140822","article-title":"Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology biologics register","volume":"70","author":"Verstappen","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib44","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cgh.2012.10.024","article-title":"Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure","volume":"11","author":"Zelinkova","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","article-title":"Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature","volume":"76","author":"Berthelot","year":"2009","journal-title":"Jt Bone Spine"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4321\/S1130-01082012000200003","article-title":"Is safety infliximab during pregnancy in patients with inflammatory bowel disease?","volume":"104","author":"Arg\u00fcelles-Arias","year":"2012","journal-title":"Rev Esp Enfermedades Dig"},{"issue":"9","key":"10.1016\/j.jaad.2023.10.072_bib47","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/ibd.21583","article-title":"Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy","volume":"17","author":"Schnitzler","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.072_bib48","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/medicina58060780","article-title":"Oversight and management of women with psoriasis in childbearing age","volume":"58","author":"Bucur","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib49","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/annrheumdis-2021-221036","article-title":"Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy","volume":"81","author":"Ghalandari","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2023.10.072_bib50","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3389\/fimmu.2017.01123","article-title":"Immunological changes in blood of newborns exposed to anti-TNF-\u03b1 during pregnancy","volume":"8","author":"Esteve-Sol\u00e9","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib51","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ijwd.2021.06.007","article-title":"Rethinking biologic and pregnancy research: the importance of assessing postpartum immunosuppression of the infant","volume":"7","author":"Abel","year":"2021","journal-title":"Int J Womens Dermatology"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.072_bib52","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/ibd\/izz110","article-title":"Anti-TNF therapy in pregnant women with inflammatory bowel disease: effects of therapeutic strategies on disease behavior and birth outcomes","volume":"26","author":"Julsgaard","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib54","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.jaad.2023.10.072_bib55","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/gutjnl-2019-319129","article-title":"Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life","volume":"70","author":"Kanis","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40413-016-0120-5","article-title":"International consensus (ICON): allergic reactions to vaccines","volume":"9","author":"Dreskin","year":"2016","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cpt.1827","article-title":"Assessment of placental disposition of infliximab and etanercept in women with autoimmune diseases and in the ex\u00a0vivo perfused placenta","volume":"108","author":"Eliesen","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaad.2023.10.072_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jri.2016.04.284","article-title":"Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in\u00a0vitro transcytosis and ex\u00a0vivo human placental transfer","volume":"116","author":"Porter","year":"2016","journal-title":"J Reprod Immunol"},{"issue":"9","key":"10.1016\/j.jaad.2023.10.072_bib59","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/pds.4261","article-title":"Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use","volume":"26","author":"Carman","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib60","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2023.10.072_bib61","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221087650","article-title":"Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol","volume":"14","author":"Clowse","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jaad.2023.10.072_bib62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fphar.2021.621247","article-title":"Biologics during pregnancy and breastfeeding among women with rheumatic diseases: safety clinical evidence on the road","volume":"12","author":"Beltagy","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib63","article-title":"The impact of gender and sex in psoriasis: what to be aware of when treating women with psoriasis","volume":"8","author":"Guillet","year":"2022","journal-title":"Int J Womens Dermatology"},{"key":"10.1016\/j.jaad.2023.10.072_bib64","series-title":"Dupixent (Dupilumab) Injections [Package Insert]","year":"2017"},{"issue":"10","key":"10.1016\/j.jaad.2023.10.072_bib65","article-title":"Reported pregnancy outcomes in women with severe atopic dermatitis treated with dupilumab: a systematic review","volume":"66","author":"Akuffo-Addo","year":"2023","journal-title":"J Cutan Med Surg"},{"issue":"12","key":"10.1016\/j.jaad.2023.10.072_bib66","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.jaip.2022.08.013","article-title":"Safety of biologics for atopic diseases during pregnancy","volume":"10","author":"Shakuntulla","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15237","article-title":"Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy","volume":"35","author":"Gracia-Darder","year":"2022","journal-title":"Dermatol Ther"},{"issue":"10","key":"10.1016\/j.jaad.2023.10.072_bib68","doi-asserted-by":"crossref","first-page":"E484","DOI":"10.1111\/1346-8138.16033","article-title":"Case of atopic eczema treated with dupilumab throughout conception, pregnancy, and lactation","volume":"48","author":"Kage","year":"2021","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib69","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000515246","article-title":"Atopic dermatitis treated safely with dupilumab during pregnancy: a case report and review of the literature","volume":"13","author":"Lobo","year":"2021","journal-title":"Case Rep Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13223-022-00650-w","article-title":"The use of dupilumab in severe atopic dermatitis during pregnancy: a case report","volume":"18","author":"Akhtar","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.072_bib71","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ced.15049","article-title":"Severe atopic dermatitis treated successfully with dupilumab throughout pregnancy","volume":"47","author":"Costley","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2023.10.072_bib72","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jdcr.2020.08.001","article-title":"Dupilumab for the treatment of severe atopic dermatitis in a pregnant patient: a case report","volume":"6","author":"Mian","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2023.10.072_bib73","series-title":"Adbry (Tralokinumab-Idrm) Injection [Package Insert]","year":"2021"},{"issue":"9","key":"10.1016\/j.jaad.2023.10.072_bib74","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/apt.17224","article-title":"Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study","volume":"56","author":"Avni-Biron","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib75","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/apt.16192","article-title":"Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study","volume":"53","author":"Wils","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/bjd.17086","article-title":"Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies","volume":"180","author":"Watson","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.10.072_bib77","series-title":"SILIQ (Brodalumab) [Package Insert]","year":"2017"},{"key":"10.1016\/j.jaad.2023.10.072_bib78","series-title":"Cosentyx (Secukinumab) [Package Insert]","year":"2023"},{"key":"10.1016\/j.jaad.2023.10.072_bib79","series-title":"Taltz (Ixekizumab) [Package Insert]","year":"2016"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.072_bib80","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/bjd.16901","article-title":"Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database","volume":"179","author":"Warren","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib81","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamadermatol.2020.5595","article-title":"Pregnancy outcomes in women with moderate-to-severe psoriasis from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"157","author":"Kimball","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.10.072_bib82","series-title":"Tremfya (Guselkumab) [Package Insert]","year":"2020"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.072_bib83","doi-asserted-by":"crossref","first-page":"AB27","DOI":"10.1016\/j.jaad.2020.06.196","article-title":"15036 Pregnancy outcomes in women exposed to guselkumab: experience from the clinical development program","volume":"83","author":"Kimball","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.10.072_bib84","series-title":"Ilumya (Tildrakizumab-Asmn) Injection [Package Insert]","year":"2018"},{"key":"10.1016\/j.jaad.2023.10.072_bib85","series-title":"SKYRIZI (Risankizumab-Rzaa) [Package Insert]","year":"2022"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib86","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bjd.18897","article-title":"Outcomes of pregnancies from the tildrakizumab phase I\u2013III clinical development programme","volume":"183","author":"Haycraft","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib87","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14931","article-title":"Considerations on inhibition of IL-23 in psoriatic women of childbearing potential","volume":"34","author":"Russo","year":"2021","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib88","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10103-011-0895-0","article-title":"Effect of narrowband ultraviolet B phototherapy on serum folic acid levels in patients with psoriasis","volume":"26","author":"El-Saie","year":"2011","journal-title":"Lasers Med Sci"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib89","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/archdermatol.2011.1614","article-title":"Narrowband UV-B phototherapy during pregnancy and folic acid depletion","volume":"148","author":"Park","year":"2012","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.072_bib90","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1054\/mehy.1997.0697","article-title":"A possible link between neural tube defects and ultraviolet light exposure","volume":"52","author":"Jablonski","year":"1999","journal-title":"Med Hypotheses"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib91","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archderm.1991.01680030067008","article-title":"Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis","volume":"127","author":"Stern","year":"1991","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib92","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/archderm.1993.01680240060006","article-title":"Psoralen photochemotherapy (PUVA) and pregnancy","volume":"129","author":"Gunnarskog","year":"1993","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib93","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.berh.2013.07.005","article-title":"Managing lupus patients during pregnancy","volume":"27","author":"Lateef","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488606775252584","article-title":"Antimalarial drugs in pregnancy: a review","volume":"1","author":"Nosten","year":"2008","journal-title":"Curr Drug Saf"},{"issue":"9","key":"10.1016\/j.jaad.2023.10.072_bib95","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00002018-200427090-00002","article-title":"Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes","volume":"27","author":"Brabin","year":"2004","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib96","first-page":"49","article-title":"Skin changes and safety profile of topical products during pregnancy","volume":"15","author":"Putra","year":"2022","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2023.10.072_bib97","series-title":"Cellcept (Mycophenolate Mofetil) [Package Insert]","year":"2022"},{"key":"10.1016\/j.jaad.2023.10.072_bib98","series-title":"Rituxan (Rituximab) Injection [Package Insert]","year":"2010"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib99","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1542\/neo.22-1-e7","article-title":"Update on the use of intravenous immunoglobulin in pregnancy","volume":"22","author":"D\u2019Mello","year":"2021","journal-title":"Neoreviews"},{"key":"10.1016\/j.jaad.2023.10.072_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101527","article-title":"Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: a double-blind, randomised, placebo-controlled trial","volume":"50","author":"Yamada","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13223-022-00660-8","article-title":"Intravenous immunoglobulins improve live birth rate among women with underlying immune conditions and recurrent pregnancy loss: a systematic review and meta-analysis","volume":"18","author":"Habets","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib102","doi-asserted-by":"crossref","first-page":"290.e1","DOI":"10.1016\/j.ajog.2020.09.007","article-title":"Hydroxychloroquine early in pregnancy and risk of birth defects","volume":"224","author":"Huybrechts","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib103","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s10067-022-06462-y","article-title":"The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities","volume":"42","author":"Ye","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.072_bib104","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s10067-022-06496-2","article-title":"Hydroxychloroquine significantly decreases the risk of preeclampsia in pregnant women with autoimmune disorders: a systematic review and meta-analysis","volume":"42","author":"Liu","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.reprotox.2008.05.053","article-title":"The safety of cetirizine during pregnancy. A prospective observational cohort study","volume":"26","author":"Weber-Schoendorfer","year":"2008","journal-title":"Reprod Toxicol"},{"issue":"9","key":"10.1016\/j.jaad.2023.10.072_bib106","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/00002018-200831090-00006","article-title":"Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis","volume":"31","author":"Schwarz","year":"2008","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.072_bib107","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0002-9378(96)70059-5","article-title":"Diphenhydramine overdose during pregnancy: lessons from the past","volume":"175","author":"Brost","year":"1996","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib108","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.reprotox.2005.03.005","article-title":"Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy","volume":"20","author":"Serreau","year":"2005","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.jaad.2023.10.072_bib109","series-title":"Vistaril (Hydroxyzine Pamoate) Capsules [Package Inset]","year":"2019"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib110","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib111","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijwd.2017.01.005","article-title":"A review of the safety of cosmetic procedures during pregnancy and lactation","volume":"3","author":"Trivedi","year":"2017","journal-title":"Int J Womens Dermatology"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.072_bib112","first-page":"665","article-title":"Safety of skin care products during pregnancy","volume":"57","author":"Bozzo","year":"2011","journal-title":"Can Fam Physician"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib113","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/009841098158863","article-title":"Human in\u00a0vivo and in\u00a0vitro hydroquinone topical bioavailability, metabolism, and disposition","volume":"54","author":"Wester","year":"1998","journal-title":"J Toxicol Environ Health A"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib114","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.trstmh.2006.06.007","article-title":"The cosmetic use of skin-lightening products during pregnancy in Dakar, Senegal: a common and potentially hazardous practice","volume":"101","author":"Mah\u00e9","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/JCAS.JCAS_226_20","article-title":"Dermatologic and cosmetic procedures in pregnancy","volume":"15","author":"Garg","year":"2022","journal-title":"J Cutan Aesthet Surg"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib116","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijwd.2019.05.002","article-title":"New changes in pregnancy and lactation labelling: review of dermatologic drugs","volume":"5","author":"Koh","year":"2019","journal-title":"Int J Womens Dermatology"},{"issue":"12","key":"10.1016\/j.jaad.2023.10.072_bib117","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/bdra.10095","article-title":"Topically applied minoxidil may cause fetal malformation: a case report","volume":"67","author":"Smorlesi","year":"2003","journal-title":"Birth Defects Res Part A Clin Mol Teratol"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.072_bib118","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/1947-2714.185029","article-title":"Comparative study of efficacy and safety of topical squaric acid dibutylester and diphenylcyclopropenone for the treatment of alopecia areata","volume":"8","author":"Tiwary","year":"2016","journal-title":"N Am J Med Sci"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib119","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12016-017-8620-9","article-title":"Alopecia areata: a comprehensive review of pathogenesis and management","volume":"54","author":"Tr\u00fceb","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s13555-022-00854-3","article-title":"Treatment of acne vulgaris during pregnancy and lactation: a narrative review","volume":"13","author":"Ly","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2023.10.072_bib121","series-title":"Soolantra (Ivermectin) [Package Insert]","year":"1996"},{"issue":"8856","key":"10.1016\/j.jaad.2023.10.072_bib122","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/0140-6736(93)90868-H","article-title":"Multiple congenital defects associated with maternal use of topical tretinoin","volume":"341","author":"Lipson","year":"1993","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jaad.2023.10.072_bib123","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5694\/j.1326-5377.1998.tb139031.x","article-title":"Topical tretinoin and fetal malformations","volume":"168","author":"Colley","year":"1998","journal-title":"Med J Aust"},{"issue":"8854","key":"10.1016\/j.jaad.2023.10.072_bib124","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/0140-6736(93)91004-6","article-title":"First trimester topical tretinoin and congenital disorders","volume":"341","author":"Jick","year":"1993","journal-title":"Lancet"},{"issue":"8794","key":"10.1016\/j.jaad.2023.10.072_bib125","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0140-6736(92)90854-V","article-title":"Ear malformation in baby born to mother using tretinoin cream","volume":"339","author":"Camera","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.10.072_bib126","series-title":"Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk","author":"Briggs","year":"2021"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib127","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaad.2018.10.023","article-title":"Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review","volume":"80","author":"Liszewski","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.10.072_bib128","series-title":"Winlevi (Clascoterone) Cream [Package Insert]","year":"2020"},{"issue":"8","key":"10.1016\/j.jaad.2023.10.072_bib129","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003088-200443080-00001","article-title":"Drug transfer and metabolism by the human placenta","volume":"43","author":"Syme","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.072_bib130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00003088-199427010-00005","article-title":"Review of \u03b2-lactam antibiotics in pregnancy: the need for adjustment of dosage schedules","volume":"27","author":"Heikkil\u00e4","year":"1994","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.072_bib131","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/AAC.12.5.630","article-title":"Hepatotoxicity of erythromycin estolate during pregnancy","volume":"12","author":"McCormack","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaad.2023.10.072_bib132","series-title":"Rifadin (Rifampin) Capsule USP [Package Insert]","year":"2020"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.072_bib133","first-page":"87","article-title":"Haemorrhagic disease of the newborn in the offspring of rifampicin and isoniazid treated mothers","volume":"29","author":"Eggermont","year":"1976","journal-title":"Acta Paediatr Belg"},{"issue":"9","key":"10.1016\/j.jaad.2023.10.072_bib134","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/1471-0528.15119","article-title":"The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis","volume":"125","author":"Yefet","year":"2018","journal-title":"BJOG"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.072_bib135","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2706","article-title":"The use of systemic and topical fluoroquinolones","volume":"138","author":"Jackson","year":"2016","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.072_bib136","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1517\/14740338.2016.1133584","article-title":"Revisiting doxycycline in pregnancy and early childhood \u2013 time to rebuild its reputation?","volume":"15","author":"Cross","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib137","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jama.1981.03320040015021","article-title":"First-trimester drug use and congenital disorders","volume":"246","author":"Jick","year":"1981","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jaad.2023.10.072_bib138","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/1471-0528.15293","article-title":"Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study","volume":"125","author":"Rotem","year":"2018","journal-title":"BJOG"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.072_bib139","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s13224-021-01586-8","article-title":"Common antifungal drugs in pregnancy: risks and precautions","volume":"71","author":"Patel","year":"2021","journal-title":"J Obstet Gynecol India"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.072_bib140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamadermatol.2020.0142","article-title":"Evaluation of association between oral and topical terbinafine use in pregnancy and risk of major malformations and spontaneous abortion","volume":"156","author":"Andersson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2023.10.072_bib141","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jdv.14297","article-title":"Topical antiviral and antifungal medications in pregnancy: a review of safety profiles","volume":"31","author":"Patel","year":"2017","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.jaad.2023.10.072_bib142","series-title":"Kerydin (Tavaborole) [Package Insert]","year":"2014"},{"key":"10.1016\/j.jaad.2023.10.072_bib143","series-title":"Jublia (Efinaconazole) [Package Insert]","year":"2014"},{"issue":"8525","key":"10.1016\/j.jaad.2023.10.072_bib144","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(87)92015-0","article-title":"Griseofulvin teratology, including two thoracopagus conjoined twins","volume":"329","author":"Rosa","year":"1987","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.072_bib145","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4103\/0019-5154.193659","article-title":"Safety of topical medications for scabies and lice in pregnancy","volume":"61","author":"Patel","year":"2016","journal-title":"Indian J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224001099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224001099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T01:55:03Z","timestamp":1736301303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224001099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":145,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0190962224001099"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.10.072","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of dermatologic medications in pregnancy and lactation: An update - Part I: Pregnancy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.10.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}